Last April, the Centers for Medicare and Medicaid Services (CMS) decided to limit the coverage of the controversial Alzheimer’s drug Aduhelm and similar drugs…
Reporter Phil Gutis, a board member for emerging Alzheimer’s advocacy group Voices of Alzheimer’s, takes a hard look at what more the Centers for…
The Centers for Medicare and Medicaid Services finalized its decision to limit the coverage of Alzheimer’s drug Aduhelm and future monoclonal antibodies. In February…
It seems like, following the FDA’s controversial July 2021 approval of Biogen’s Alzheimer’s drug Aduhelm, everyone is mad at someone. Here are the main…